Zacks Investment Research reaffirmed their hold rating on shares of Vernalis (OTCMKTS:VNLPY) in a research report released on Saturday.

According to Zacks, “Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs. “

Vernalis (VNLPY) opened at $0.26 on Friday. Vernalis has a 1 year low of $0.26 and a 1 year high of $0.61. The firm has a market cap of $61.90, a P/E ratio of -2.36 and a beta of 0.59.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/vernalis-vnlpy-rating-reiterated-by-zacks-investment-research/1808647.html.

About Vernalis

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Get a free copy of the Zacks research report on Vernalis (VNLPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vernalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis and related companies with MarketBeat.com's FREE daily email newsletter.